Leerink Partners has subtly lowered its FY2025 earnings prediction for Abbott Laboratories, now expecting a profit of $5.14 ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as analysts view the market reaction as “overly punitive” and see an ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...